HUTCHMED (China)
HUTCHMED (China)'s revenue fell 13.0% to $548 million in fiscal 2025. Its operating margin was −7.1%, down from −6.9% a year earlier. Free cash flow was −$79 million.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity.
What HUTCHMED (China) does
HUTCHMED is a drug company that started in China in 2000. It discovers, develops and sells targeted medicines for cancer and for diseases of the immune system. Three of its own drugs are sold in China under the names Orpathys, Elunate and Sulanda. Outside China, its partner Takeda sells fruquintinib as Fruzaqla, which has been approved in 38 countries, including the United States, Europe and Japan. AstraZeneca is its partner for savolitinib, and it has 15 more drug candidates in clinical trials.
Its consolidated revenue was $548.5 million in 2025. It comes from its cancer and immunology business, through sales of its drugs and payments from partners, and from what it calls Other Ventures, which make, market and distribute prescription drugs in China and brought in $263.0 million. Its own sales team in China numbers about 780 people.
In April 2025 it sold most of its stake in Shanghai Hutchison Pharmaceuticals, a joint venture with Shanghai Pharmaceuticals, keeping 5%. At the end of 2025 it had 1,796 full-time employees.
Its biggest risks, as it describes them
- Its drug candidates may fail in clinical trials or not win approval, after long and costly development.
- Its reliance on partners such as AstraZeneca and Takeda to develop and sell its drugs outside China.
- Losing government reimbursement in China, or price cuts through centralized buying, could hurt sales.
- Changes in Chinese law and policy, limits on moving money out of China, and the need to keep many permits.
- Its shares in the United States could be delisted if US regulators cannot inspect its auditor.
Income statement
From fiscal 2016 to 2025, earnings per share grew 43.6% a year and net income 50.3% a year, as new shares raised the share count by 46% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 1,012 | 631 | 886 | 836 | 1,367 |
| Debt incl. finance leases | — | 18 | 110 | 106 | 118 |
| Net debt (negative means net cash) | — | −613 | −776 | −730 | −1,249 |
| Net debt to EBITDA | — | — | −29.2x | — | — |
| Debt to equity | — | 0.0x | 0.1x | 0.1x | 0.1x |
| Interest coverage | −554.6x | −625.3x | 24.2x | −15.2x | −13.7x |
| Current ratio | 3.9x | 2.4x | 2.7x | 2.8x | 5.0x |
| Quick ratio | 3.8x | 2.2x | 2.6x | 2.7x | 4.8x |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 7 of 9 | 4 of 9 | 4 of 9 |
| Rule of 40 | 118.8% | −27.6% | −27.3% |
| Altman Z'' | 2.89 | 2.80 | 6.45 |
| Accruals ratio | −10.3% | 2.9% | 34.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Fail |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Pass | Fail | Fail |
| Debt fell relative to assets | Fail | Pass | Pass |
| Current ratio rose | Pass | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Fail | Fail |
| Revenue rose relative to assets | Pass | Fail | Fail |
| F-score | 7 of 9 | 4 of 9 | 4 of 9 |
Compare
Put HUTCHMED (China) side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| HUTCHMED (China) | FY25 | −13.0% | −7.1% | −14.4% | — | — | 4 | |
| Mirum Pharmaceuticals | FY25 | 54.7% | −4.2% | 10.5% | −7.1% | −34.9x | 5 | Compare |
| BridgeBio Pharma | FY25 | 126.3% | −104.2% | −89.0% | — | — | 3 | Compare |
| Insmed | FY25 | 66.7% | −205.6% | −159.6% | — | — | 5 | Compare |
| OPKO Health | FY25 | −14.9% | −19.4% | −31.4% | −7.0% | — | 4 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 216 | 241 | 214 | 205 | 228 | 356 | 426 | 838 | 630 | 548 |
| Revenue growth | 21.2% | 11.6% | −11.2% | −4.3% | 11.3% | 56.2% | 19.7% | 96.5% | −24.8% | −13.0% |
| Gross profit | 67 | 71 | — | — | — | — | 115 | 454 | 281 | 212 |
| Research and development | 67 | 76 | 114 | 138 | 175 | 299 | 387 | 302 | 212 | 148 |
| Operating income | −47 | −53 | −93 | −146 | −197 | −328 | −408 | 18 | −44 | −39 |
| Net income | 12 | −27 | −75 | −106 | −126 | −195 | −361 | 101 | 38 | 457 |
| Diluted EPS (US$) | 0.02 | −0.04 | −0.11 | −0.16 | −0.18 | −0.25 | −0.43 | 0.12 | 0.04 | 0.52 |
| Diluted shares (millions) | 600 | 617 | 664 | 666 | 698 | 793 | 847 | 869 | 873 | 873 |
| Cash flow | ||||||||||
| Cash from operations | −10 | −9 | −33 | −81 | −62 | −204 | −269 | 219 | 0 | −65 |
| Capital expenditure | 4 | 5 | 6 | 9 | 8 | 16 | 37 | 33 | 18 | 14 |
| Free cash flow | −14 | −14 | −39 | −89 | −70 | −221 | −305 | 187 | −17 | −79 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 1 | 1 | 6 | 0 | 13 | 27 | 48 | 9 | 36 | 0 |
| Acquisitions | 0 | 0 | 0 | 8 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | — | — | — | — | — | — | — | — | — | — |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 104 | 358 | 301 | 217 | 435 | 1,012 | 631 | 886 | 836 | 1,367 |
| Debt incl. finance leases | 47 | 30 | 27 | 27 | 27 | — | 18 | 110 | 106 | 118 |
| Total assets | 342 | 598 | 532 | 465 | 724 | 1,373 | 1,029 | 1,280 | 1,274 | 1,753 |
| Total liabilities | 138 | 113 | 120 | 152 | 205 | 333 | 393 | 536 | 502 | 502 |
| Shareholders' equity | 184 | 462 | 389 | 288 | 484 | 987 | 610 | 730 | 760 | 1,238 |
| Margins and ratios | ||||||||||
| Gross margin | 31.0% | 29.6% | — | — | — | — | 27.0% | 54.1% | 44.6% | 38.7% |
| Operating margin | −21.6% | −22.1% | −43.3% | −71.5% | −86.3% | −92.2% | −95.6% | 2.2% | −6.9% | −7.1% |
| Net margin | 5.4% | −11.1% | −34.9% | −51.8% | −55.1% | −54.7% | −84.6% | 12.0% | 6.0% | 83.3% |
| Free cash flow margin | −6.4% | −5.8% | −18.3% | −43.7% | −30.7% | −62.0% | −71.6% | 22.3% | −2.8% | −14.4% |
| Rule of 40 (growth + FCF margin) | 14.8% | 5.8% | −29.6% | −48.0% | −19.4% | −5.7% | −51.9% | 118.8% | −27.6% | −27.3% |
| Return on capital | −27.6% | −27.9% | −50.0% | −89.0% | −133.3% | — | — | — | — | — |
| Return on equity | 8.7% | −8.3% | −17.6% | −31.3% | −32.6% | −26.5% | −45.2% | 15.0% | 5.1% | 45.7% |
| Return on assets | 4.1% | −5.7% | −13.2% | −21.3% | −21.1% | −18.6% | −30.0% | 8.7% | 3.0% | 30.2% |
| Net debt to EBITDA | — | — | — | — | — | — | — | −29.2x | — | — |